Yield and Coverage of Active Case Finding Interventions for Tuberculosis Control: A Systematic Review and Meta-analysis

Ruth W. Deya, Linnet N. Masese, Walter Jaoko, Jeremiah Chakaya Muhwa, Lilian Mbugua, David J. Horne, and Susan M. Graham

1University of Nairobi, Institute of Tropical and Infectious Diseases, Nairobi, Kenya
2University of Washington, Department of Medicine, Seattle, USA
3University of Nairobi, Department of Medical Microbiology, Nairobi, Kenya
4Kenyatta University, Medicine, Dermatology, Psychiatry and Therapeutics, Nairobi, Kenya
5Liverpool School of Tropical Medicine, Liverpool, UK
6University of Washington, Department of Global Health, Seattle, WA, USA
7University of Washington, Department of Epidemiology, Seattle, WA, USA

Correspondence should be addressed to Ruth W. Deya; ruthgitau@gmail.com

Received 30 March 2021; Revised 28 May 2022; Accepted 9 June 2022; Published 30 June 2022

Academic Editor: Juraj Ivanyi

Copyright © 2022 Ruth W. Deya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Active case finding (ACF) for tuberculosis (TB) is a key strategy to reduce diagnostic delays, expedite treatment, and prevent transmission. Our objective was to identify the populations, settings, screening and diagnostic approaches that optimize coverage (proportion of those targeted who were screened) and yield (proportion of those screened who had active TB) in ACF programs. Methods. We performed a comprehensive search to identify studies published from 1980-2016 that reported the coverage and yield of different ACF approaches. For each outcome, we conducted meta-analyses of single proportions to produce estimates across studies, followed by meta-regression to identify predictors. Findings. Of 3,972 publications identified, 224 met criteria after full-text review. Most individuals who were targeted successfully completed screening, for a pooled coverage estimate of 93.5%. The pooled yield of active TB across studies was 3.2%. Settings with the highest yield were internally-displaced persons camps (15.6%) and healthcare facilities (6.9%). When compared to symptom screening as the reference standard, studies that screened individuals regardless of symptoms using microscopy, culture, or GeneXpert®MTB/RIF (Xpert) had 3.7% higher case yield. In particular, microbiological screening (usually microscopy) as the initial test, followed by culture or Xpert for diagnosis had 3.6% higher yield than symptom screening followed by microscopy for diagnosis. In a model adjusted for use of Xpert testing, approaches targeting persons living with HIV (PLWH) had a 4.9% higher yield than those targeting the general population. In all models, studies targeting children had higher yield (4.8%-5.7%) than those targeting adults. Conclusion. ACF activities can be implemented successfully in various populations and settings. Screening yield was highest in internally-displaced person and healthcare settings, and among PLWH and children. In high-prevalence settings, ACF approaches that screen individuals with laboratory tests regardless of symptoms have higher yield than approaches focused on symptomatic individuals.

1. Introduction

In 2019, the World Health Organization (WHO) estimated global tuberculosis (TB) incidence at 10.0 million cases [1]. Although TB incidence declined globally by approximately 2.3% between 2018 and 2019, the goal of the WHO END TB Strategy is to reduce incidence by 10% per year by 2025. TB transmission is facilitated by the late diagnosis of many active TB cases [2–4]. Moreover, contacts of index cases with early-stage active TB are often missed due to low sensitivity of sputum microbiological tests [5]. Although efforts to increase detection have recently accelerated with
the “Find. Treat. All” Initiative [6], TB case reporting remains suboptimal: only 7.1 million (71%) of new TB cases were reported to the WHO in 2019 [1, 6–8].

If left untreated, a person with infectious TB will transmit Mycobacterium tuberculosis to 10–15 people per year [1]. To decrease transmission, active case finding (ACF) strategies may be required. ACF is defined as any strategy to search for undiagnosed active TB disease in a defined population, usually high-risk groups, high-prevalence congregate settings or communities, or contacts of TB patients [9–11]. After cases of active TB diseases have been diagnosed, ACF activities may be followed by testing for and treatment of latent TB infection, as is often done during contact investigations [12]. Unlike countries with low TB incidence, most low- and middle-income countries do not conduct contact investigations and have placed a low priority on ACF activities [12, 13].

In 2018, the WHO issued a recommendation that high-burden countries evaluate household contacts of bacteriologically confirmed pulmonary TB cases aged 5 years and over, treating them for active or latent TB infection as indicated [6]. Planning additional ACF activities will require evaluation of TB prevalence in specific settings and populations, consideration of optimal diagnostic tests, and assessment of the cost-effectiveness of such activities [8, 14].

While studies show that screening increases case-finding in the short-term and identifies less severe cases [15, 16], there is no published meta-analysis of factors associated with higher yield (i.e., proportion of those screened who had active TB) and coverage (i.e., proportion of those targeted who were screened) of ACF activities. An analysis summarizing evidence from the published literature on the yield and coverage of ACF activities in countries with high TB prevalence would inform and help focus the efforts of policymakers and TB program managers faced with the dual TB-HIV epidemic to END TB. Our objective in the current study was therefore to identify the populations, settings, and screening and diagnostic approaches that optimize yield and coverage in ACF programs.

2. Methods

2.1. Inclusion criteria. This systematic review followed PRISMA guidelines [17]. Studies were eligible for inclusion if they were conducted in a country with high TB prevalence (>100 per 100,000) and reported results of an intervention designed to detect undiagnosed active TB. Following the WHO definition of systematic screening for active TB, we defined ACF as “the systematic identification of people at risk for TB disease, in a predetermined target group, by assessing symptoms and using tests, examinations or other procedures that can be applied rapidly” [18]. Interventions could be any TB screening method or combination of methods, including symptom screening, clinical assessment, chest X-ray (CXR), sputum acid-fast bacillus (AFB) microscopy, sputum culture, or GeneXpert® MTB/RIF testing (Xpert), followed by diagnostic work-up and treatment if indicated. We included studies reporting at least one of the following primary outcomes: (1) number of newly diagnosed active TB cases, (2) screening yield, or (3) screening coverage. Populations targeted for screening were categorized as: general population, contacts of active TB cases, individuals at high risk for active TB (e.g., persons living with HIV [PLWH], persons with diabetes mellitus, pregnant women, hospital inpatients), individuals at high risk for TB exposure (e.g., refugees, homeless persons, prisoners, residents of other congregate settings), or workers in high-risk settings for TB exposure (e.g., miners, healthcare workers). Population-based surveys, observational studies (i.e., cross-sectional or cohort studies) and randomized trials were eligible. We excluded studies whose primary outcome was the diagnosis of latent TB infection including those only testing for TB infection (with a TB skin test or interferon-gamma release assay).

2.2. Search strategy. With the help of a research librarian, we searched PubMed, EMBASE, Global Health Database, Cochrane Library Central Register of Controlled Trials, Scopus and the WHO Library, using MeSH terms for PubMed and comparable terms for the other databases. We consulted the WHO International Clinical Trials Registry Platform for ongoing trials. Full details of the search strategy are included in Supplemental Material 1. We limited the search to English-language studies conducted between January 1, 1980 (after the emergence of the HIV epidemic) and September 18, 2016. For studies that used different screening modalities for different populations, including separate arms of clinical trials, results were evaluated separately for each population. If two different papers reported data from the same study population, we included only the latter one or the one with the most complete outcome reporting.

2.3. Citation screening and data abstraction. We used End-Note to import citations and remove duplicates. Two researchers screened each abstract for relevance to the study of ACF outcomes, with a third reviewer resolving discrepancies. If the results of abstract screening were unclear, the article was included for the next stage of screening. After identification of potentially eligible studies, four reviewers independently conducted full text review on 40 randomly selected papers to standardize methods for confirming eligibility, extracting data, and rating study quality. We extracted study description, setting, and study populations included from included papers. If a study conducted screening activities in two distinct populations (e.g., children and adults), these were considered two different “populations” with separate outcomes. For each population, we abstracted the tests, examinations or other procedures that were applied, and the basis upon which individuals were selected for each test, examination, or procedures were applied. The screening method was defined as any test applied to the entire study population to identify individuals who would receive further active TB workup. The diagnostic method was defined as any TB diagnostic test applied to individuals who screened positive with the initial screening method. We also abstracted the number targeted for TB screening; number completing TB screening; number of new active TB cases identified; number initiating and completing TB treatment (if reported); number of cases reported as sputum-, culture-
or Xpert-positive; number with CXR abnormalities; and data on rifampicin resistance or multi-drug-resistant TB (MDR-TB) (i.e., resistance at least to rifampicin and isoniazid).

2.4. Quality review. A modified Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data was used to rate study quality [19]. Studies were rated as “yes,” “no,” or “unclear” on the following criteria: adequate description of subjects and setting, use of valid TB screening and diagnostic methods, use of standardized and reliable screening and diagnosis measures, and adequacy of screening participation (defined as coverage ≥80%). A final overall quality rating was assigned to each included article: “high” if all four quality metrics were rated as “yes,” “moderate” if any metric was rated “unclear”, and “low” if any metric was rated “no”.

2.5. Screening and diagnostic categories. Based on the abstracted chart data, we assigned one screening method and one diagnostic method category to each population screened. We divided screening modalities into four categories: (1) symptom screening, (2) microbiological testing (microscopy, culture, or Xpert) with or without symptoms screening, (3) CXR with or without symptoms screening, and (4) tuberculin skin tests (TST). Any study that used a microbiological test (microscopy, culture, or GeneXpert MTB/RIF) was assigned as “lab testing”; any study that used CXR and not lab tests was assigned as “CXR”. Any study that used symptom screening and not lab tests or CXR was assigned as “symptom screening”. Finally, one remaining study was assigned as “TST” because it did not use lab testing. CXR or symptom screening to identify individuals who qualify for next step in TB diagnosis.

We divided diagnostic modalities into three categories: (1) culture and/or Xpert, (2) microscopy and (3) CXR. Any study that used culture and/or Xpert was assigned as “culture and/or Xpert”; any study that used microscopy and neither culture nor Xpert was assigned as “microscopy” and any study that used CXR and not culture, Xpert or microscopy was assigned as “CXR”. Finally, we created a combined “algorithm” variable incorporating both screening and diagnostic modalities in the six categories, as illustrated in Figure 1.

2.6. Statistical analysis. Descriptive statistics were used to summarize data, with number and percentage for categorical data and median and interquartile range for continuous data. Study attributes summarized included study design; WHO geographical region; setting (community, hospital or clinic, prison or residential facility, workplace, other settings); type of population targeted (contacts, PLWH, general population, high risk for TB exposure, high risk for active TB); and participant age (adults [defined as age ≥15 years], children or both) study quality and year of publication.

We conducted a separate meta-analysis of single proportions for each of the two outcomes (yield and coverage). For each specific population, the two outcomes of interest were expressed as proportions, using the appropriate numerators and denominators abstracted from the publication. After excluding studies with missing numerators or denominators, we used random effects modeling to derive pooled yield and pooled coverage proportion estimates across populations. This was done using Stata’s ’metaprop’ command to calculate the pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances [20]. Score-based confidence intervals [21] were calculated based on a random effects model using the method of DerSimonian and Laird, with the estimate of heterogeneity being taken from the inverse-variance fixed-effect model [22]. Heterogeneity across populations was evaluated using Cochrane’s Q test statistic and the I^2 statistic.

Meta-analysis was followed by meta-regression using the study and population attributes described above (i.e., study design, WHO region, recruitment setting, type of population screened, population age category, year of publication, study quality and either screening and diagnostic modality as two separate variables or as a combined algorithm variable) as independent predictors of yield and coverage. We used the ‘metareg’ function in Stata to perform a random-effects meta-regression using aggregate-level data while taking into account the within-study standard error of the dependent variable (i.e., yield or coverage) [23]. Results reported as beta coefficients with 95% confidence intervals and interpretable as differences relative to the reference category. Predictors of yield and of coverage that were significant at p<0.10 in bivariable analysis were included in multivariable analysis. We ran three multivariable models. Model 1 included screening and diagnostic modalities as separate predictors. Model 2 used the combined algorithm variable that incorporated both screening and diagnostic modality. Model 3 evaluated the use of Xpert for diagnosis as a binary yes/no predictor, to determine if Xpert was an important driver of increased yield. Two sensitivity analyses were conducted, one excluding studies of populations with children (since diagnostic approaches in children differ from those in adults) and one excluding low-quality studies. Statistical analyses were performed using Stata version 16.0 (College Station, Texas).

3. Results

3.1. Included studies. Our search identified 4,722 records, of which 750 were duplicates or not in English language. We screened the remaining 3,972 abstracts and identified 224 papers for inclusion in analysis (Figure 2). These 224 studies reported coverage results for 256 unique populations and yield for 277 unique populations. As an example of a study that presented results of different populations, Banu et al. [24] screened inmates at the time of prison entry and also conducted active case finding among inmates already incarcerated, and these were counted as two separate populations. Overall, 25,652,139 individuals were screened, with 55,549 new TB cases identified. Table 1(a) presents a summary of study attributes and Table 1(b) presents a summary of populations included in the studies. Supplemental Material 2 provides a detailed list of all included studies.

Most studies took place in Africa (68.3%) or Southeast Asia (22.7%) and were observational cross-sectional or
(i) All participants undergo screening and diagnostic testing at baseline

| Screening categories |
|----------------------|
| Symptom screening    |
| Lab screening (microscopy, culture or genexpert) |
| Chest radiography    |
| Tuberculin skin test (TST)* |

(i) The screening category was classified as TST only if this was the sole screening method applied, since TST results are not reliable for predicting active TB disease.

**Combined algorithm**

1. Symptom screening then microscopy
2. Symptom screening then chest radiography
3. Symptom screening then culture or genexpert
4. Chest radiography then culture or genexpert
5. Lab screening then culture or genexpert
6. Other combination

**Figure 1: Combined Screening and Diagnostic Algorithm Variable.**

**Identification**
Records identified through database searching
(n = 4,722)

**Screening**
Records after duplicates and non-english records removed
(n = 3,972)

**Eligibility**
Records screened
(n = 3,972)

**Included**
Full-text articles assessed for eligibility
(n = 332)

**Records excluded as ineligible**
(n = 3,640)
3070 = Not relevant or latent TB infection screening
570 = Low-prevalence setting (<100 TB cases per 100,000)

**Full-text articles excluded, with reasons**
(n = 108)
47 = Passive case finding
5 = Latent TB infection
9 = Duplicate study population
11 = Not primary data
5 = Low incidence setting
29 = Relevant screening #s missing
2 = not relevant

**Studies included in qualitative and quantitative synthesis**
(meta-analysis)  
(n = 224)

**Figure 2: PRISMA Diagram.**
cohort study designs (80.0%). Sites were the community (52.7%), hospitals or primary health centers (32.9%), prisons or other residential institutions (7.6%), workplaces (6.1%), or camps for internally-displaced persons (0.7%). No studies focused on immigrants or refugee settings. Adults comprised 180 populations (65.0%), both adults and children 56 populations (20.2%), and children only 41 populations (14.8%).

Most studies used one of six screening and diagnostic algorithms, with the two most commonly used algorithms being [a] symptom screening followed by sputum culture or Xpert (30.0%) and [b] symptom screening followed by sputum microscopy (19.5%). Only one study, by Nachega et al., applied TST as the first screening step, using clinical criteria, CXR, microscopy and culture to confirm active TB.

Table 1: (a) Characteristics of 277 unique populations within the 224 studies.

| Characteristic                        | N (%) |
|---------------------------------------|-------|
| WHO region                            |       |
| Africa                                | 153 (68.3) |
| South East Asia                       | 51 (22.7) |
| Eastern Mediterranean                 | 10 (4.5) |
| Western Pacific                       | 5 (2.2) |
| The Americas                          | 4 (1.8) |
| Other (multi-regional study)          | 1 (0.5) |
| Quality rating                        |       |
| High                                  | 136 (60.7) |
| Moderate                              | 25 (11.2) |
| Low                                   | 63 (28.1) |
| Year of publication                   |       |
| 1980 to 1999                          | 22 (7.9) |
| 2000 to 2010                          | 66 (23.8) |
| 2011 to 2016                          | 189 (68.2) |
| HIV assessment                        |       |
| Testing                               | 132 (47.7) |
| Self-report                           | 7 (2.5) |
| Other (chart review)                  | 2 (0.7) |
| Not reported                          | 136 (49.1) |

Table 1: Continued.

| Characteristics of 277 populations | N (%) |
|------------------------------------|-------|
| HIV assessment                     |       |
| Testing                            | 132 (47.7) |
| Self-report                        | 7 (2.5) |
| Other (chart review)               | 2 (0.7) |
| Not reported                       | 136 (49.1) |

| Treatment initiation                |       |
| Reported                            | 88 (31.8) |
| Not reported                        | 189 (68.2) |

| Treatment completion                |       |
| Reported                            | 27 (9.8) |
| Not reported                        | 250 (90.3) |

| Screening modality c                |       |
| Symptom screening                   | 182 (65.7) |
| Lab testing (microscopy, culture, or GeneXpert MTB/RIF) | 58 (21.0) |
| CXR                                 | 36 (13.0) |
| TST                                 | 1 (0.3) |

| Diagnostic modality               |       |
| Culture &/or GeneXpert MTB/RIF    | 165 (59.6) |
| Microscopy                         | 61 (22.0) |
| CXR                                | 51 (18.4) |

| Screening and diagnostic algorithm |       |
| Symptom screen – Microscopy        | 54 (19.5) |
| Symptom screen – CXR               | 44 (15.9) |
| Symptom screen – Culture/Xpert     | 84 (30.3) |
| CXR – Culture/Xpert               | 29 (10.5) |
| Lab screen d – Culture/Xpert       | 51 (18.4) |
| Other e                            | 15 (5.4) |

| Screening and diagnostic algorithm |       |
| Symptom screen – Microscopy        | 54 (19.5) |
| Symptom screen – CXR               | 44 (15.9) |
| Symptom screen – Culture/Xpert     | 84 (30.3) |
| CXR – Culture/Xpert               | 29 (10.5) |
| Lab screen d – Culture/Xpert       | 51 (18.4) |
| Other e                            | 15 (5.4) |

CXR = Chest x-ray, RCT = Randomized control trial, TST = Tuberculin skin test.

High risk for TB exposure: health care worker, prisoner, refugee. High risk for active TB: diabetes mellitus, pregnancy, miners. Tuberculin skin tests were included as part of screening in 5 studies classified as “lab testing,” 14 studies classified as “CXR” and 15 studies classified as “symptom screening.” Includes initial TB screening by AFB smear (94%), culture (71%), or GeneXpert MTB/RIF (8%). Other = microscopy for screening and diagnosis (5), CXR for screening and diagnosis (5), CXR for screening then microscopy for diagnosis (2), TST for screening then culture for diagnosis (1), and microscopy for screening then CXR for diagnosis (2).
status among individuals who were TST-positive [25]. HIV status was assessed in 141 populations (50.9%). Few studies reported treatment initiation (88 or 31.8%) or treatment completion rates (27 or 9.8%). Most of the 224 studies were of high quality (136 or 60.7%), while 25 were of moderate quality (11.2%) and 63 were of low quality (28.1%).

3.2. Pooled results for ACF coverage. Figure 3 presents pooled coverage estimates (white bars) by region and other population and study attributes. Overall, the pooled coverage among the 256 populations that reported coverage was 93.5% (95% confidence interval [CI], 92.2% – 94.7%). Coverage was relatively high (>90%) in most studies, but was notably lower in the one study that used a quasi-randomized controlled trial (RCT) design (52.0%) and reported coverage data. This study, called the ZAMSTAR study, tested a community-level enhanced TB case-finding approach including sputum testing versus household-level combined TB and HIV care in Zambia and South Africa, and had a calculated coverage of 52.0% [26]. Supplemental material 3 includes details of the numbers targeted and screened in each category.

3.3. Meta-regression of ACF coverage. Supplemental material 4 includes details of the meta-regression of ACF coverage. Predictors of coverage significant in bivariable analyses included study type (p =0.002), study quality (0.003) diagnostic modality (p =0.02), and algorithm category (p =0.02). In a multivariable model including only study type, diagnostic modality, and quality as predictors, coverage in quasi-RCT studies was lower by 38.6% compared to cross-sectional studies. Studies that used culture or Xpert for diagnosis had 9.7% lower coverage than studies using microscopy for diagnosis. Moderate and low-quality studies had 12.1% and 10.3% lower coverage than high-quality studies, respectively, with a similar trend in all 3 models. In a model including study type, algorithm category and quality as predictors, coverage in quasi-RCT studies was lower by 37.8% in the quasi-RCT studies compared to cross-sectional studies. Coverage was significantly lower by 12.1% when symptom screening was followed by culture or Xpert compared to symptom screening followed by microscopy and lower by 11.4% when laboratory testing was the initial screening method.

3.4. Pooled results for ACF yield. Figure 3 presents pooled yield estimates (dark orange bars) by region and other population and study attributes. The pooled yield of new TB cases in all 277 populations was 3.2% (95% CI, 2.9%–3.4%). The highest yield was in internally-displaced persons settings (15.6%) and in a multiregional study, at 12.0% [27], while the lowest yield was in the six populations included in the two quasi-RCT studies and in studies published from 1980-1999 (both 0.9%). The screening approach with the lowest yield was symptom screening followed by microscopy (1.9%). In terms of settings, the highest yield was reported in ACF activities at internally-displaced persons camp (15.6%) and healthcare facilities (6.9%). Active case finding among PLWH had the highest yield (9.0%) in terms of population screened. Heterogeneity was high (overall $I^2 = 99.7\%$) due to the wide variety of populations, settings, screening and diagnostic approaches, and study designs. Yield was lower in studies rated as low quality, but study quality as a categorical variable was not a significant predictor of yield in regression analyses. Supplemental material 5 includes details of the numbers screened and diagnosed in each category.

3.5. Meta-regression of ACF yield. Table 2 presents bivariable and multivariable meta-regression results for the pooled yield outcome. Predictors of yield that were significant in bivariable analysis were study design (p =0.08), WHO geographical region (p =0.02), recruitment setting (p <0.001), population screened (p <0.001), age (p =0.02), screening modality (p =0.01), and algorithm used (p =0.02). The three multivariable models are presented in separate columns of Table 2. In Model 1, which included screening and diagnostic modalities as separate predictors, studies that screened children exclusively had 5.7% higher yield when compared with studies that screened only adults and studies that screened individuals regardless of symptoms using microscopy, culture, or Xpert had 3.7% higher case yield than studies that focused on symptoms as the initial screen. In Model 2, which used the combined algorithm variable incorporating both screening and diagnostic modality, studies that screened children exclusively had 5.6% higher yield when compared with studies that screened only adults, and studies that used microbiological screening (94% of which used microscopy) as the initial test, followed by culture or Xpert for diagnosis had 3.6% higher yield than symptom screening followed by microscopy for diagnosis. In Model 3, where the binary Xpert variable indicating diagnosis by Xpert was used rather than the screening or approach variables, studies that screened children exclusively had 4.8% higher yield when compared with studies that screened only adults, and approaches targeting PLWH had a 4.9% higher yield than those targeting the general population. Of note, age was the only predictor of yield significant in all multivariable models (at $p =0.005$, $p =0.005$ and $p =0.02$ in multivariable Models 1, 2 and 3, respectively). Sensitivity analyses excluding studies of children and excluding low-quality studies had similar results to the main analyses (details not shown).

4. Discussion

Our systematic review and meta-analysis identified the pooled yield and coverage of various ACF approaches in 277 study populations across 224 studies carried out in 30 high-incidence countries. We highlight how various screening and diagnostic modalities perform when employed in a variety of settings, with respect to both coverage and yield. ACF coverage was generally high, with a pooled estimate of 93.5%, indicating high acceptability in most studies. ACF yield was estimated at 3.2% overall, and was higher in studies targeting children than in those targeting adults; this finding was consistent in all meta-regression analyses. ACF yield was also significantly higher in PLWH compared to the general population, and yield estimates were high in health care settings and settings where internally-displaced persons were temporarily settled. In addition, ACF yield
was higher when microbiological screening methods were applied to individuals regardless of symptoms. These findings should mitigate concerns about the higher cost of sensitive and specific laboratory tests, especially when ACF targets populations or settings where TB transmission or incidence rates are high.

Coverage, or successful screening completion, is influenced by many factors, including the acceptability of screening and complexity of screening procedures. In the studies we reviewed, ACF coverage was generally high, reflecting high acceptability of screening in high TB burden countries. While coverage estimates were somewhat lower in studies that screened using laboratory-based methods, this was likely due to barriers to access (e.g., transportation costs, limited business hours) for repeat sample collections [28]. Although microscopic detection of AFB is more specific for TB diagnosis than the presence of TB symptoms, laboratory-based screening can introduce barriers to screening completion, compromising coverage and early TB detection [28–30]. In our review, recruitment settings with

![Figure 3: Pooled Estimates of Yield and Coverage by Study and Population Attributes; Coverage is defined as total number of people of screened/total number of people targeted for screening. Yield is defined as total number of people with active TB/total number of people screened. Bars indicate 95% confidence intervals of random effects meta-analyses.](image-url)
Table 2: Meta-regression of Predictors of Yield of Active TB Cases following Active Case Finding Activities.

| Predictors of yield proportion | Bivariabe Analysis | Multivariable model 1: Screening and diagnosis separate | Multivariable model 2: Combined approach | Multivariable model 3: Diagnosis by GeneXpert MTB/RIF |
|--------------------------------|---------------------|--------------------------------------------------------|------------------------------------------|-----------------------------------------------------|
| Overall                        | Beta (95% CI)       | P value       | Beta (95% CI)       | P value       | Beta (95% CI)       | P value       | Beta (95% CI)       | P value       |
| Study design                   |                     |              |                      |              |                      |              |                      |              |
| Cross-sectional                | Reference           | Reference    | Reference            | Reference    | Reference            | Reference    |
| Prospective                    | 0.98 (-1.56 to 3.52)| -1.12 (-3.66 to 1.41)| -1.11 (-3.65 to 1.42)| -1.10 (-3.62 to 1.42) |
| RCT                            | 0.96 (-2.82 to 4.74)| 0.79 (-3.14 to 4.72) | 1.00 (-2.92 to 4.93) | 0.02 (-3.79 to 3.83) |
| Surveys                        | -3.55 (-7.36 to 0.27)| -2.66 (-6.43 to 1.10) | -2.51 (-6.26 to 1.24) | -2.04 (-5.73 to 1.64) |
| Retrospective chart review     | 4.74 (-0.46 to 9.94)| 0.57 (-4.70 to 5.84) | 1.52 (-3.81 to 6.85) | 0.84 (-4.40 to 6.08) |
| Quasi RCT                      | -3.78 (-10.87 to 2.72)| -5.16 (-11.47 to 1.16) | -5.44 (-11.75 to 0.86) | -3.84 (-9.95 to 2.28) |
| WHO region                     | 0.02                | 0.21         | 0.28                 | 0.15         |
| Africa                         | Reference           | Reference    | Reference            | Reference    |
| Americas                       | -1.2 (-7.67 to 5.26) | -3.37 (-10.52 to 3.77) | -3.18 (-10.37 to 4.00) | -2.29 (-9.44 to 4.86) |
| Eastern Mediterranean          | -4.31 (-9.89 to 1.28)| -3.51 (-9.03 to 2.01) | -3.37 (-8.86 to 2.12) | -3.38 (-8.88 to 2.13) |
| S.E. Asia                      | -3.50 (-5.78 to -1.22)| -2.40 (-4.93 to 0.13) | -2.11 (-4.63 to 0.41) | -2.54 (-4.88 to -0.19) |
| Western Pacific                | 5.21 (-2.80 to 13.22)| 3.36 (-4.54 to 11.26) | 3.45 (-4.30 to 11.19) | 4.67 (-2.96 to 12.30) |
| Multi- regional                | 6.04 (-11.32 to 23.40)| 6.92 (-9.80 to 23.64) | 7.52 (-9.15 to 24.19) | 5.99 (-10.76 to 22.74) |
| Recruitment setting            | <0.001              | 0.12         | 0.10                 | 0.26         |
| Community based                | Reference           | Reference    | Reference            | Reference    |
| Hospitals or clinics           | 5.73 (3.50 to 7.95) | 2.37 (-1.18 to 5.92) | 2.56 (-0.98 to 6.10) | 2.09 (-1.44 to 5.62) |
| Prisons or residential facility| 0.18 (-3.57 to 3.93) | 0.31 (-5.56 to 6.18) | 0.25 (-5.60 to 6.10) | 1.24 (-4.74 to 7.22) |
| Workplaces                     | -0.23 (-4.23 to 3.78) | -2.32 (-8.30 to 3.67) | -2.25 (-8.18 to 3.69) | -0.78 (-6.59 to 5.02) |
| Internally-displaced persons camps | 11.65 (-0.63 to 23.92) | 12.97 (-1.03 to 26.96) | 13.04 (-0.94 to 27.03) | 11.96 (-2.05 to 25.97) |
| Type of population screened    | <0.001              | 0.34         | 0.38                 | 0.14         |
| General population             | Reference           | Reference    | Reference            | Reference    |
| Contacts                       | 1.68 (-0.92 to 4.29) | -1.15 (-4.42 to 2.13) | -0.96 (-4.23 to 2.31) | 0.16 (-3.31 to 3.00) |
| PLWH                           | 7.52 (4.8 to 10.23) | 3.60 (-0.75 to 7.95) | 3.34 (-0.97 to 7.64) | 4.85 (0.74 to 8.97) |
| High risk for TB exposure<sup>a</sup> | -0.39 (-3.66 to 2.87) | 0.74 (-4.55 to 6.03) | 1.02 (-4.26 to 6.31) | -0.62 (-5.92 to 4.67) |
| High risk for active TB<sup>b</sup> | 2.09 (-1.33 to 5.51) | -0.17 (-4.82 to 5.16) | -0.05 (-5.03 to 4.94) | 0.68 (-4.25 to 5.61) |
| Population age group           | 0.02                | 0.005        | 0.005                | 0.02         |
| Adults                         | Reference           | Reference    | Reference            | Reference    |
| Adults and children            | -0.61 (-3.19 to 1.98)| 2.33 (-0.78 to 5.45) | 2.22 (-0.90 to 5.35) | 1.81 (-1.28 to 4.90) |
| Children only                  | 4.13 (0.99 to 7.28) | 5.71 (2.28 to 9.15) | 5.61 (2.22 to 8.99) | 4.76 (1.45 to 8.07) |
| Predictors of yield proportion | Bivariant Analysis | Multivariable model 1: | Multivariable model 2: | Multivariable model 3: |
|--------------------------------|-------------------|-----------------------|-----------------------|-----------------------|
|                                |                   | Screening and diagnosis separate | Combined approach | Diagnosis by GeneXpert MTB/RIF |
| Year of publication            |                   |                       |                       |                       |
| 2011 to 2016                   | Reference         |                       |                       |                       |
| 2000 to 2010                   | 1.06 (-1.43 to 3.55) |                       |                       |                       |
| 1980 to 1999                   | -0.88 (-4.66 to 2.90) |                       |                       |                       |
| Study quality rating           |                   |                       |                       |                       |
| High quality                   | Reference         |                       |                       |                       |
| Moderate quality               | -1.51 (16.82 to 13.79) |                       |                       |                       |
| Low quality                    | 0.63 (-7.56 to 8.82) |                       |                       |                       |
| Screening modality             |                   |                       |                       |                       |
| Symptom screening              | Reference         |                       |                       |                       |
| CXR                            | 0.14 (-2.97 to 3.24) | 1.95 (-1.61 to 5.52) |                       |                       |
| Lab Screening^c                 | 4.16 (1.60 to 6.71) | 3.66 (0.68 to 6.64) |                       |                       |
| TST                            | 3.27 (-9.35 to 15.90) | -3.97 (-16.18 to 8.25) |                       |                       |
| Diagnostic modality            |                   |                       |                       |                       |
| Microscopy                     | Reference         |                       |                       |                       |
| Culture &/or GeneXpert MTB/RIF | 1.68 (-0.87 to 4.22) | -0.40 (-3.02 to 2.22) |                       |                       |
| CXR                            | 2.52 (-0.75 to 5.79) | 0.21 (-3.00 to 3.42) |                       |                       |
| Combined screening and diagnostic algorithm | | | | |
| Symptom – Microscopy           | Reference         |                       |                       |                       |
| Symptom – CXR                  | 2.32 (-1.10 to 5.75) |                       | 0.03 (-3.37 to 3.43) |                       |
| Symptom – Culture/Xpert        | -0.03 (-2.96 to 2.90) | -1.05 (-3.92 to 1.82) |                       |                       |
| CXR – Culture/Xpert            | 0.62 (-3.25 to 4.49) | 1.29 (-2.91 to 5.49) |                       |                       |
| Lab^c – Culture/Xpert          | 5.02 (1.74 to 8.30) | 3.60 (0.08 to 7.28) |                       |                       |
| Other^d                        | 1.97 (-2.84 to 6.79) | 0.17 (-5.04 to 4.70) |                       |                       |
| Diagnostic test using GeneXpert MTB/RIF | | | | |
| GeneXpert MTB/RIF not used     | Reference         |                       |                       | -1.67 (-4.53 to 1.20) |
| GeneXpert MTB/RIF used         | 1.99 (-0.98 to 4.97) |                       |                       |                       |

^a High risk for TB exposure: health care worker, prisoner, refugee. ^b High risk for active TB: diabetes mellitus, pregnancy, miners. ^c Includes screening using AFB smear (94%), culture (71%), or GeneXpert MTB/RIF (8%). ^d Other = microscopy for screening and diagnosis (5), CXR for screening and diagnosis (5), CXR for screening then microscopy for diagnosis (2), TST for screening then culture for diagnosis (1), and microscopy for screening then CXR for diagnosis (2).
the highest coverage were prisons and residential facilities (96.4%), supporting ACF activities in these settings. Studies in our review with low coverage cited challenges with logistics, specimen handling, and reaching highly mobile populations. Specifically, the ZAMSTAR Quasi RCT was an ambitious study that enumerated and sought to consent populations. Specifical logistics, specimen handling, and reaching highly mobile in our review with low coverage cited challenges with coverage, supporting ACF activities in these settings. Studies with the highest coverage were prisons and residential facilities (96.4%).

Our study had several limitations. First, heterogeneity was high due to the large variety of screening and diagnostic modalities, populations, settings, and study designs in our sample. We addressed this by conducting a random effects meta-analysis and meta-regression, as well as by adjusting for variables including year of publication, WHO region and study design. Second, we present only studies that were peer-reviewed and published in English. Third, 28% were rated as low quality and 8% of studies were missing data on coverage, one of our main outcomes. Fourth, the majority of published studies followed WHO recommendations on TB screening (i.e., interview for TB symptoms and HIV status) and diagnosis (i.e., microscopy or sputum culture if available) [37], and the number of studies researching ACF innovations was small during the time period of our search. Fifth, given the use of ACF and the heterogeneity in study design, population, and durations we are cannot directly compare TB yield in the research study populations to published WHO country data on annual TB case rates. We did not identify any studies of refugees or immigrants currently living in high-prevalence countries. We used a hierarchical classification of screening and diagnostic modalities making it challenging to disentangle the effects of individual modalities. However, these modalities were applied jointly and represent pragmatic TB screening or diagnostic activities.

In conclusion, ACF is an important adjunct to passive TB case detection that will be needed to improve TB control efforts globally. Approaches using microbiological testing, especially innovations such as Xpert testing, and targeting settings or populations with higher risk may increase the yield of ACF activities. Screening completion was successful in most populations and settings. In addition, the relationship between ACF approaches and the full TB care cascade is an important gap in the evidence base that should be addressed in future research.

Data Availability

Data available within the article or its supplementary materials. The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials. All, Share upon request. Data available on request from the authors. The data that support the findings of this study are available from the corresponding author, [RD], upon reasonable request. Basic, Share upon Request.

Conflicts of Interest

“The author(s) declare(s) that there are no conflicts of interest regarding the publication of this paper.”
Authors’ Contributions

RWD and SMG developed the study protocol and funding application. RWD conducted the primary systematic review data extraction, conducted data analysis and drafted the report. LNM conducted the primary systematic review data extraction made critical comments that helped in the interpretation of results and reviewed the final report. SMG and DJH participated in study conception, conducted quality review and arbitrated conflicts in data extraction decisions, helped in writing sections of the report and reviewed the final report. LM conducted data entry and cleaning and participated in manuscript review. WJ and CM provided institutional support, made critical comments that helped in the interpretation of results and reviewed the final report.

Funding

The authors acknowledge financial support from WHO/EMRO under the Special Programme for Research and Training in Tropical Diseases (TDR) – Short-term training grants for research capacity strengthening and knowledge management.

Acknowledgments

The authors acknowledge financial support from WHO/EMRO under the Special Programme for Research and Training in Tropical Diseases (TDR) – Short-term training grants for research capacity strengthening and knowledge management (to RWD). We would like to acknowledge the invaluable contribution of Diana Louden at University of Washington Health Sciences Library in conducting the search strategy. We thank Monisha Sharma for her help with meta-analysis and meta-regression and for assistance with figures, and the anonymous reviewer who provided constructive feedback and greatly improved our manuscript. We would like to acknowledge that preliminary results of this work were presented in part at a University of Washington scholars’ seminar for the Kenya Research and Training Center, Global Health Department on January 8, 2020. We would like to acknowledge that this abstract was presented in part at the “51st Union World Conference on Lung Health” as an E-poster No. EP24 331 23 on 20-24th October 2020.

Supplementary Materials

Supplementary 1. Supplemental material 1: Systematic Review Search Strategy.

Supplementary 2. Supplemental material 2: List of 224 included studies and raw outcome data.

Supplementary 3. Supplemental Material 3: Table showing Pooled Estimates of Screening Coverage; Based on 256 populations with Data on Numerator and Denominator.

Supplementary 4. Supplemental Material 4: Table showing Meta-regression of Predictors of Coverage of Active TB Cases following Active Case Finding Activities for 256 Unique Populations.

Supplementary 5. Supplemental Material 5: Table Showing Pooled Estimates of TB Yield, Based on 277 Populations with Data on Numerator and Denominator.

References

[1] Organization, W H O, Global Tuberculosis Report, Geneva, 2020.
[2] S. Bello, R. F. Afolabi, D. T. Ajayi et al., “Empirical evidence of delays in diagnosis and treatment of pulmonary tuberculosis: systematic review and meta-regression analysis,” BMC Public Health, vol. 19, no. 1, p. 820, 2019.
[3] D. G. Storla, S. Yimer, and G. A. Bjune, “A systematic review of delay in the diagnosis and treatment of tuberculosis,” BMC Public Health, vol. 8, no. 1, p. 15, 2008.
[4] C. T. Sreeramareddy, Z. Z. Qin, S. Satyanarayana, R. Subbaraman, and M. Pai, “Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review,” The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 3, pp. 255–266, 2014.
[5] B. R. Bloom, R. Atun, T. Cohen et al., Tuberculosis in Major Infectious Diseases, K. K. Holmes, S. Bertozzi, B. R. Bloom, and P. Jha, Eds., The International Bank for Reconstruction and Development/The World Bank, Washington (DC), 3rd edition, 2017.
[6] WHO, Global tuberculosis report, Technical Report Series, In World Health Organization, 2019.
[7] World Health Organization, Global tuberculosis report 2015, Geneva: World Health Organization, 20th edition, 2015.
[8] M. Bates, J. O’Grady, P. Mwaba et al., “Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients,” PLoS One, vol. 7, no. 7, article e40774, 2012.
[9] E. L. Corbett, S. Charalambous, V. M. Moloi et al., “Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 6, pp. 673–679, 2004.
[10] H. Getahun, M. Harrington, R. O’Brien, and P. Nunn, “Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes,” Lancet, vol. 369, no. 9578, pp. 2042–2049, 2007.
[11] H. Getahun, W. Kittikraisak, C. M. Heilig et al., “Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies,” PLoS Medicine, vol. 8, no. 1, article e1000391, 2011.
[12] M. Begun, A. T. Newall, G. B. Marks, and J. G. Wood, “Contact tracing of tuberculosis: a systematic review of transmission modelling studies,” PLoS One, vol. 8, no. 9, article e72470, 2013.
[13] G. J. Fox, S. E. Barry, W. J. Britton, and G. B. Marks, “Contact investigation for tuberculosis: a systematic review and meta-analysis,” The European Respiratory Journal, vol. 41, no. 1, pp. 140–156, 2013.
[14] J. Morrison, M. Pai, and P. C. Hopewell, “Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 8, no. 6, pp. 359–368, 2008.
[15] L. Blok, S. Sahu, J. Creswell, S. Alba, R. Stevens, and M. I. Bakker, "Comparative meta-analysis of tuberculosis contact investigation interventions in eleven high burden countries," *PLoS One*, vol. 10, no. 3, article e0119822, 2015.

[16] K. Kranzer, H. Afnan-Holmes, K. Tomlin et al., "The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review," *The International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 4, pp. 432–446, 2013.

[17] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *Journal of Clinical Epidemiology*, vol. 62, no. 10, pp. 1006–1012, 2009.

[18] WHO, Consolidated guidelines on tuberculosis: module 2: screening - systematic screening for tuberculosis disease, World Health Organization, CC BY-NC-SA 3.0 IGO, Licence, Geneva, 2021.

[19] Z. Munn, S. Moola, K. Lisy, D. Riitano, and C. Tufanaru, "Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data," *International Journal of Evidence-Based Healthcare*, vol. 13, no. 3, pp. 147–153, 2015.

[20] M. F. Freeman and J. W. Tukey, "Transformations related to the angular and the square root," *Annals of Mathematical Statistics*, vol. 21, no. 4, pp. 607–611, 1950.

[21] E. B. Wilson, "Probable inference, the law of succession, and statistical inference," *Journal of the American Statistical Association*, vol. 22, no. 158, pp. 209–212, 1927.

[22] V. N. Nyaga, M. Arbyn, and M. Aerts, "Metaprop: a Stata command to perform meta-analysis of binomial data," *Arch Public Health*, vol. 72, no. 1, p. 39, 2014.

[23] R. M. Harbord and J. P. Higgins, "Meta-regression in Stata," *The Stata Journal*, vol. 8, no. 4, pp. 493–519, 2008.

[24] S. Banu, M. T. Rahman, M. K. M. Uddin et al., "Effect of active case finding on prevalence and transmission of pulmonary tuberculosis in Dhaka central jail, Bangladesh," *PLoS One*, vol. 10, no. 5, article e0124976, 2015.

[25] J. Nachega, J. Coetzee, T. Adendorff et al., "Tuberculosis active case-finding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa," *AIDS*, vol. 17, no. 9, pp. 1398–1400, 2003.

[26] H. Ayles, M. Muyoyeta, E. du Toit et al., "Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial," *The Lancet*, vol. 382, no. 9899, pp. 1183–1194, 2013.

[27] S. Swindells, L. Komarow, S. Tripathy et al., "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group protocol A5253," *International Journal Of Tuberculosis And Lung Disease*, vol. 17, no. 4, pp. 532–539, 2013.

[28] S. B. Marahatta, R. K. Yadav, D. Giri et al., "Barriers in the access, diagnosis and treatment completion for tuberculosis patients in central and western Nepal: a qualitative study among patients, community members and health care workers," *PLoS One*, vol. 15, no. 1, article e0227293, 2020.

[29] E. Van Ginderdeuren, J. Bassett, C. Hanrahan, L. Mutunga, and A. Van Rie, "Health system barriers to implementation of TB preventive strategies in South African primary care facilities," *PLoS One*, vol. 14, no. 2, article e0212035, 2019.

[30] I. Ayakaka, S. Ackerman, J. M. Ggita et al., "Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach," *Implementation Science*, vol. 12, no. 1, p. 33, 2017.

[31] L. Page-Shipp, W. Stevens, D. Clark et al., "Successes, challenges and lessons from a novel deployment of Xpert MTB/RIF at a major south African public event [Short Communication]," *International Journal of Tuberculosis and Lung Disease*, vol. 18, no. 4, pp. 438–440, 2014.

[32] Stop Tb Partnership Childhood Tb Subgroup and W H O, "Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children," *The official journal of the International Union against Tuberculosis and Lung Disease*, vol. 10, no. 11, pp. 1205–1211, 2006.

[33] S. M. LaCourse, F. M. Chester, G. Preidis et al., "Use of xpert for the diagnosis of pulmonary tuberculosis in severely malnourished hospitalized Malawian children," *Pediatric Infectious Disease Journal*, vol. 33, no. 11, pp. 1200–1202, 2014.

[34] J. M. Topley, D. Maher, and L. N. Mbewe, "Transmission of tuberculosis to contacts of sputum positive adults in Malawi," *Archives of Disease in Childhood*, vol. 74, no. 2, pp. 140–143, 1996.

[35] B. D. Agins, D. J. Ikeda, M. J. A. Reid, E. Goosby, M. Pai, and A. Cattamanchi, "Improving the cascade of global tuberculosis care: moving from the ‘what’ to the ‘how’ of quality improvement," *The Lancet Infectious Diseases*, vol. 19, no. 12, pp. e437–e443, 2019.

[36] R. Subbaraman, T. Jhaveri, and R. R. Nathavitharana, "Closing gaps in the tuberculosis care cascade: an action-oriented research agenda," *Journal Of Clinical Tuberculosis And Other Mycobacterial Diseases*, vol. 19, article 100144, 2020.

[37] WHO, In Systematic Screening for Active Tuberculosis: Principles and Recommendations, Geneva, 2013.